WO1997039756A1 - Use of phosphonic acid esters for the treatment of functional disorders of the brain and depression - Google Patents
Use of phosphonic acid esters for the treatment of functional disorders of the brain and depression Download PDFInfo
- Publication number
- WO1997039756A1 WO1997039756A1 PCT/US1997/006469 US9706469W WO9739756A1 WO 1997039756 A1 WO1997039756 A1 WO 1997039756A1 US 9706469 W US9706469 W US 9706469W WO 9739756 A1 WO9739756 A1 WO 9739756A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dimethyl
- phosphonate
- trichloroethane
- thiophosphonate
- trifluoroethane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the invention relates to the use of phosphonic acid esters for the treatment and prevention of functional disorders of the brain and depression, and to new compounds and their production,
- DE-1 078370 discloses phosphonic acid esters used for the control of insects.
- metrifonate is suitable for the treatment of Alzheimer's disease (US 4,950,658) .
- the assumed mode of action is that metrifonate is converted slowly into the organo- phosphoric acid ester dichlorvos and thereby induces a long-lasting inhibition of cholinesterase.
- butonate was proposed as a suitable precursor for etrifonate/dichlorvos (B.R. Holmstedt and I. Nordgren, in Cholinergic Basis for Alzheimer Therapy (R.E. Becker and E. Giacobini, eds), Birkhauser, Boston, 155-161, 1S91) .
- the compounds of the formula (I) are suitable for the treatment and prevention of cognitive and affective diseases, and in particular for the treatment of senile and presenile dementia, dementia of the Alzheimer's type, AIDS-related dementia, cognitive deficits in Parkinson's and Huntington's disease or functional disorders of the brain as a result of infarction, multi-infarct dementia (MID), primary degenerative dementia (PDP) and other forms of dementia and for the treatment of depression.
- MID multi-infarct dementia
- PDP primary degenerative dementia
- R ⁇ represents hydrogen or methyl
- the invention also relates to the following compounds: dimethyl ( 1-tert. -butylcarbonyloxy-2 , 2,2-trichloroethane)- phosphonate dimethyl ( l-methanesulphonyloxy-2 ,2,2-trichloro ⁇ thane)- phosphonate, imethyl ( 1-ethanesulphonyloxy-2,2,2-trichloroethane)- phosphonate, dimethyl ( l-methoxycarbonyloxy-2, 2, 2-trichloroethane)- phosphonate, dimethyl ( l-acetyloxy-2, 2, 2-trifluoroethane)-phosphonate, dimethyl ( l-methoxycarbonyloxy-2, 2,2-trifluoroethane)- phosphonate , imethyl ( l-propylcarbonyloxy-2, 2 , 2-trifluoroethane)- phosphonate , dimethyl ( 1-methanesulphonyloxy-2, 2,2-tri
- the present invention also relates to the use of the following compounds which are already known:
- Alkali metal and alkaline earth metal hydrides such as lithium, sodium, potassium and calcium hydride, alkali metal and alkaline earth metal hydroxides, such as lithium, sodium, potassium and calcium hydroxide, alkali metal and alkaline earth metal carbonates and hydrogen carbonates, such as sodium and potassium carbonate or sodium and potassium hydrogen carbonate as well as calcium carbonate, alkali metal acetates, such as sodium and potassium acetate, alkali metal alcoholates, such as sodium and potassium tert.-butylate, and furthermore basic nitrogen compounds such as trimethylamine, triethylamine, tripropylamine, tributylamine, ethyldiisopropylamine, ethyldicyclohexylamine, N,N-dimethylbenzylamine, N,N-dimethyl- aniline, pyridine, 2-methyl-, 3-methyl-, 4-methyl-, 2,4
- the process for the preparation of the compounds (I) by reaction with the carboxylic anhydrides of the formula (IV) can also be carried out without diluents.
- All the usual mineral acids can be used as the catalyst.
- Preferred acids are sulphuric acid, hydrochloric acid or phosphoric acid. They are used in a quantity of 0.001 to 10 mol % .
- the compounds are usually obtained in the form of oils which in some cases cannot be distilled without decomposition, but which can be freed from the residual volatile constituents by so-called "incipient" distillation, i.e. by heating the compounds at moderately increased temperatures for relatively long periods under reduced pressure, as a result of which they are purified.
- the compounds are characterised by means of their refractive index.
- the crystalline compounds are characterised by their melting point.
- mice On the fourth day the behaviour of the animals was examined for 30 seconds in a trial cycle in which no platform was present; the period of time which the mice spent in each of the four quadrants was determined. The mice had been administered the substance to be tested or the vehicle 30 minutes or one hour before the test cycle; the selection of mice for the vehicle and test substance groups was carried out at random. Dimethyl(l-hydroxy-2,2,2-trimethylethane)-phosphonate showed an ED-JQ of 0.1-4 mg/kg after oral administration.
- the formulations are for example prepared by extending the active compounds with solvents and/or excipients, optionally using emulsifiers and/or disp ⁇ rsants, it being possible optionally to use organic solvents as auxiliary solvents where water is for example used as a diluent.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002252567A CA2252567A1 (en) | 1996-04-25 | 1997-04-17 | Use of phosphonic acid esters for the treatment of functional disorders of the brain and depression |
JP09538197A JP2000510455A (en) | 1996-04-25 | 1997-04-17 | Use of phosphonates for the treatment of brain dysfunction and depression |
BR9709300A BR9709300A (en) | 1996-04-25 | 1997-04-17 | Application of phosphonic acid esters for the treatment of functional brain diseases and depression |
EP97920431A EP0896540A1 (en) | 1996-04-25 | 1997-04-17 | Use of phosphonic acid esters for the treatment of functional disorders of the brain and depression |
AU24623/97A AU2462397A (en) | 1996-04-25 | 1997-04-17 | Use of phosphonic acid esters for the treatment of functional disorder s of the brain and depression |
SK1463-98A SK146398A3 (en) | 1996-04-25 | 1997-04-17 | Use of phosphonic acid esters for the treatment of functional disorders of the brain and depression |
IL12669897A IL126698A0 (en) | 1996-04-25 | 1997-04-17 | Use of phosphonic acid esters for the treatment of functional disorders of the brain and depression |
BG102864A BG102864A (en) | 1996-04-25 | 1998-10-22 | Application of phosphonic acid esters for the treatment of functional disorders of the brain and depressions |
NO984964A NO984964L (en) | 1996-04-25 | 1998-10-23 | Use of phosphonic esters for the treatment of functional disorders of the brain and in depression |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19616471A DE19616471A1 (en) | 1996-04-25 | 1996-04-25 | Phosphonic acid ester for the treatment of brain disorders and depression |
DE19616471.0 | 1996-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997039756A1 true WO1997039756A1 (en) | 1997-10-30 |
Family
ID=7792381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/006469 WO1997039756A1 (en) | 1996-04-25 | 1997-04-17 | Use of phosphonic acid esters for the treatment of functional disorders of the brain and depression |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0896540A1 (en) |
JP (1) | JP2000510455A (en) |
KR (1) | KR20000010611A (en) |
AR (1) | AR006870A1 (en) |
AU (1) | AU2462397A (en) |
BG (1) | BG102864A (en) |
BR (1) | BR9709300A (en) |
CA (1) | CA2252567A1 (en) |
CZ (1) | CZ343498A3 (en) |
DE (1) | DE19616471A1 (en) |
HU (1) | HUP9903366A3 (en) |
ID (1) | ID16678A (en) |
IL (1) | IL126698A0 (en) |
NO (1) | NO984964L (en) |
PL (1) | PL333464A1 (en) |
SK (1) | SK146398A3 (en) |
TR (1) | TR199802137T2 (en) |
WO (1) | WO1997039756A1 (en) |
ZA (1) | ZA973538B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1078370B (en) * | 1958-09-16 | 1960-03-24 | Norddeutsche Affinerie | Pest repellants |
US3069312A (en) * | 1960-09-28 | 1962-12-18 | California Research Corp | N-substituted dimethyl 1-carbamoyloxy-2, 2, 2-trichloroethyl phosphonates as insecticidal compositions |
GB963631A (en) * | 1962-05-16 | 1964-07-15 | Bayer Ag | Phosphorylated urethanes |
GB1001860A (en) * | 1963-08-05 | 1965-08-18 | Bayer Ag | Phosphorylated urethanes |
DE2512375A1 (en) * | 1975-03-21 | 1976-09-30 | Bayer Ag | 1-HYDROXY-2,2,2-TRICHLORAETHANE THIONOPHOSPHONIC ACID DIAL KYLESTER, METHOD FOR THEIR PRODUCTION AND THEIR USE AS INSECTICIDES |
US4950658A (en) * | 1988-12-06 | 1990-08-21 | Board Of Trustees Of Southern Illinois Univ. | Method of medical treatment of Alzheimer's disease |
-
1996
- 1996-04-25 DE DE19616471A patent/DE19616471A1/en not_active Withdrawn
-
1997
- 1997-04-17 CA CA002252567A patent/CA2252567A1/en not_active Abandoned
- 1997-04-17 SK SK1463-98A patent/SK146398A3/en unknown
- 1997-04-17 PL PL97333464A patent/PL333464A1/en unknown
- 1997-04-17 BR BR9709300A patent/BR9709300A/en not_active Application Discontinuation
- 1997-04-17 CZ CZ983434A patent/CZ343498A3/en unknown
- 1997-04-17 WO PCT/US1997/006469 patent/WO1997039756A1/en not_active Application Discontinuation
- 1997-04-17 EP EP97920431A patent/EP0896540A1/en not_active Withdrawn
- 1997-04-17 JP JP09538197A patent/JP2000510455A/en active Pending
- 1997-04-17 HU HU9903366A patent/HUP9903366A3/en unknown
- 1997-04-17 AU AU24623/97A patent/AU2462397A/en not_active Abandoned
- 1997-04-17 KR KR1019980708502A patent/KR20000010611A/en not_active Application Discontinuation
- 1997-04-17 TR TR1998/02137T patent/TR199802137T2/en unknown
- 1997-04-17 IL IL12669897A patent/IL126698A0/en unknown
- 1997-04-24 ZA ZA9703538A patent/ZA973538B/en unknown
- 1997-04-24 ID IDP971362A patent/ID16678A/en unknown
- 1997-04-25 AR ARP970101724A patent/AR006870A1/en unknown
-
1998
- 1998-10-22 BG BG102864A patent/BG102864A/en unknown
- 1998-10-23 NO NO984964A patent/NO984964L/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1078370B (en) * | 1958-09-16 | 1960-03-24 | Norddeutsche Affinerie | Pest repellants |
US3069312A (en) * | 1960-09-28 | 1962-12-18 | California Research Corp | N-substituted dimethyl 1-carbamoyloxy-2, 2, 2-trichloroethyl phosphonates as insecticidal compositions |
GB963631A (en) * | 1962-05-16 | 1964-07-15 | Bayer Ag | Phosphorylated urethanes |
GB1001860A (en) * | 1963-08-05 | 1965-08-18 | Bayer Ag | Phosphorylated urethanes |
DE2512375A1 (en) * | 1975-03-21 | 1976-09-30 | Bayer Ag | 1-HYDROXY-2,2,2-TRICHLORAETHANE THIONOPHOSPHONIC ACID DIAL KYLESTER, METHOD FOR THEIR PRODUCTION AND THEIR USE AS INSECTICIDES |
US4950658A (en) * | 1988-12-06 | 1990-08-21 | Board Of Trustees Of Southern Illinois Univ. | Method of medical treatment of Alzheimer's disease |
Non-Patent Citations (2)
Title |
---|
HOLMSTEDT B R ET AL: "TOXICOLOGICAL LIMITATIONS TO CHOLINOMIMETIC THERAPY.", BECKER, R. AND E. GIACOBINI (ED.). ADVANCES IN ALZHEIMER DISEASE THERAPY SERIES: CHOLINERGIC BASIS FOR ALZHEIMER THERAPY. X+494P. BIRKHAEUSER BOSTON: CAMBRIDGE, MASSACHUSETTS, USA;BASEL, SWITZERLAND. ILLUS. 0 (0). 1991. 155-161. ISBN: 0-8176-3566-1;, XP002034906 * |
KOCHANSKY J P ET AL: "Design of some delayed-action toxicants for baits to control red imported fire ants", J. ECON. ENTOMOL. (JEENAI,00220493);79; VOL.72 (5); PP.655-8, SCI. EDUC. ADM.;INSECT PHYSIOL. LAB.; BELTSVILLE; 20705; MD; USA, XP002034905 * |
Also Published As
Publication number | Publication date |
---|---|
CZ343498A3 (en) | 1999-02-17 |
BG102864A (en) | 1999-09-30 |
NO984964L (en) | 1998-12-22 |
PL333464A1 (en) | 1999-12-20 |
EP0896540A1 (en) | 1999-02-17 |
ZA973538B (en) | 1997-11-18 |
HUP9903366A3 (en) | 2000-08-28 |
IL126698A0 (en) | 1999-08-17 |
SK146398A3 (en) | 1999-06-11 |
DE19616471A1 (en) | 1997-10-30 |
KR20000010611A (en) | 2000-02-25 |
TR199802137T2 (en) | 1999-02-22 |
NO984964D0 (en) | 1998-10-23 |
ID16678A (en) | 1997-10-30 |
BR9709300A (en) | 1999-08-10 |
AR006870A1 (en) | 1999-09-29 |
JP2000510455A (en) | 2000-08-15 |
CA2252567A1 (en) | 1997-10-30 |
HUP9903366A2 (en) | 2000-07-28 |
AU2462397A (en) | 1997-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nugent et al. | Pyrazoline bisphosphonate esters as novel antiinflammatory and antiarthritic agents | |
SI9111099A (en) | Process for preparation of araliphatically n-substituted aminoalkanephosphinic acids | |
JPH08508245A (en) | Phosphonic acid derivative | |
WO1999003822A1 (en) | Bicyclic metabotropic glutamate receptor ligands | |
HU200465B (en) | Process for producing substituted alphaamino acids, derivatives thereof and pharmaceutical compositions comprising such compounds | |
JPH0649083A (en) | Substituted aminophosphonate derivative, its production, and medicine composition containing same | |
HUT64079A (en) | Process for producing new n-aralkyl and n-heteroaralkyl amino alakanephosphinic acids and pharmaceutical compositions comprising same as active ingredient | |
EP2240500B1 (en) | Method for synthesizing hydroxy-bisphosphonic acid derivatives | |
Nugent et al. | Carbonyl-containing bisphosphonate esters as novel antiinflammatory and antiarthritic agents | |
EP0896540A1 (en) | Use of phosphonic acid esters for the treatment of functional disorders of the brain and depression | |
CA1328113C (en) | Process for the manufacture of novel unsaturated amino acid compounds | |
MXPA98008643A (en) | Use of phosphonic acid esters for the treatment of functional transtornes of the brain and the depression | |
US20080032950A1 (en) | Neurologically-Active Compounds | |
US20050234021A1 (en) | Amino phosphonate and amino bis-phosphonate derivatives | |
FI97231B (en) | Process for the preparation of 4-substituted 2-aminoalk-3-enoic acids | |
US5489717A (en) | Glutamate (NMDA) receptor antagonists | |
CA2138331A1 (en) | Use of phosphoric acid esters and phosphonic acid esters for treating disorders of cognitive function and depressions | |
HU214628B (en) | Process for preparing amidine compounds and pharmaceutical preparatives containing them | |
US5620990A (en) | Alpha-(4-chlorophenyl)-4-[(4-fluorphenyl)-methyl]piperidine-1-ethanol esters, their preparation and their therapeutic application | |
CA2127115C (en) | Methane diphosphonic acid derivative, its production process and its pharmaceutical applications | |
WO1989004821A1 (en) | N-(biphenylmethyl)-3-hydroxyglutaramic acid and derivatives as hypocholesterolemic agents | |
EP0654035B1 (en) | Phosphonoacetic esters and acids as anti-inflammatories | |
US20070270385A1 (en) | Substituted propane phosphinic acid esters | |
JP2784921B2 (en) | Carbamate compounds | |
JPH06247965A (en) | Piperazine- and piperidineisoxazole derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97195722.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997920431 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1199800860 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1998/008643 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2252567 Country of ref document: CA Ref document number: 2252567 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 332458 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980708502 Country of ref document: KR Ref document number: 1998/02137 Country of ref document: TR Ref document number: 146398 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1998-3434 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1997920431 Country of ref document: EP Ref document number: PV1998-3434 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: PV1998-3434 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980708502 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997920431 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019980708502 Country of ref document: KR |